How Ozempic and Wegovy work — and why they're not the same medicine

Picture the moment the injection starts working

Within hours of a weekly Wegovy injection, semaglutide begins binding to GLP-1 receptors distributed throughout the body: in the hypothalamus, which governs hunger signals; in the gut wall, where it slows the rate food moves through the stomach; and in the pancreas, where it supports insulin release in response to food. The result, experienced over days and weeks, is a sustained reduction in appetite rather than a sudden crash in hunger. Many people describe eating far less than before simply because the drive to eat feels quieter, not suppressed by willpower, but by a biological signal the medicine reinstates.

That mechanism is the same whether the injection is Ozempic or Wegovy. What differs is the dose. Ozempic's licensed doses top out at 2mg for type 2 diabetes management; Wegovy climbs to 2.4mg as the original maintenance dose, with the MHRA approving a 7.2mg maintenance option in early 2026. The higher dose matters because the appetite-suppressing effect strengthens with semaglutide dose, which is why the weight-loss-focused programme uses a higher ceiling. The full mechanics of how Wegovy works are worth reading if you want to understand the titration logic alongside the biology.

The once-weekly injection arrives in a pre-filled pen. If you're prescribed Wegovy through a regulated UK pharmacy, it comes in a plain, unbranded box via DPD tracked delivery, you can follow it on your phone the same morning it dispatches. The pen itself is pre-set; there is no mixing or measuring.

Why Ozempic is not a weight-loss medicine in the UK

This is the source of most of the confusion online. Ozempic is semaglutide, Wegovy is semaglutide, and the MHRA has assessed the same active ingredient in both. But licensing is product- and indication-specific, not ingredient-specific. Ozempic holds a UK licence for type 2 diabetes, not for weight management. Wegovy holds a separate UK licence for weight management in adults with a BMI of 30 or above, or 27 or above alongside a weight-related health condition such as high blood pressure or high cholesterol.

Prescribing Ozempic for weight loss in someone without type 2 diabetes is prescribing outside the licensed indication, and the NHS medicines guidance on semaglutide is explicit on this point. The MHRA has also stated that GLP-1 medicines are not assessed for quick or cosmetic weight loss. That means anyone offering Ozempic specifically for weight-loss purposes deserves careful scrutiny. A detailed comparison of whether Wegovy and Ozempic are the same clears this up in full.

Worth knowing: Rybelsus is also semaglutide, this time as a daily tablet, but again licensed only for type 2 diabetes. The oral semaglutide product licensed for weight management is the Wegovy tablet, approved by the MHRA in June 2026. More background on semaglutide covers all four formulations side by side.

Ozempic's role in diabetes, and how that differs from Wegovy's weight-loss evidence

In type 2 diabetes, Ozempic helps lower HbA1c (a measure of average blood sugar over roughly three months) and has shown cardiovascular benefits in trial populations. The GLP-1 receptor agonist mechanism suits both purposes: insulin secretion is glucose-dependent, meaning semaglutide supports it when blood sugar is elevated but doesn't push it dangerously low in the way some older diabetes medicines can. That's one reason the class attracted attention beyond diabetes management.

The weight-loss evidence base for Wegovy comes from the STEP clinical programme. In STEP 1, published in the New England Journal of Medicine, adults with obesity achieved an average body-weight reduction of around 15% over 68 weeks at the 2.4mg dose alongside lifestyle changes. The newer 7.2mg dose produced approximately 20.7% average weight loss over 72 weeks in further trials. These are population averages from controlled settings; individual results vary, and a prescriber's assessment of suitability covers far more than a BMI number. Context about private treatment costs is available on the Wegovy cost page, including what's typically included in a private prescription price.

What is actually licensed for weight loss in the UK, and the route to get it

Two injectable medicines currently hold UK licences for weight management: Wegovy (semaglutide, Novo Nordisk) and Mounjaro (tirzepatide, Eli Lilly). Tirzepatide is a dual GIP and GLP-1 receptor agonist (activating two gut-hormone pathways rather than one) and in head-to-head trials produced greater average weight loss than semaglutide 2.4mg. NICE has appraised both: NICE TA875 recommends semaglutide within specialist weight-management services for up to two years; tirzepatide is covered under a separate NICE appraisal. NHS access involves strict and phased eligibility criteria. Private access through a regulated UK online pharmacy is the alternative for people who don't meet those criteria yet, or who don't want to wait.

If you're researching semaglutide-based treatment or want to understand whether Wegovy suits your situation, a common question is whether it's safe to mix Ozempic and Wegovy, which is worth reading before starting either medicine. At nume, every consultation is read the same day by a GPhC-registered Independent Prescriber, a real clinician, not automated screening. You can explore the options and check your eligibility with our prescribers to find out which licensed treatment, if any, is appropriate for you.